Clinical trial

Phase III Study of Gemcitabine Compared With UFT in Patients With Completely Resected Pathological Stage IB-IIIa Non Small Cell Lung Cancer

NCT00139971

Study summary

ClinicalTrials.gov

Phase III Study of Gemcitabine Compared With UFT in Patients With Completely Resected Pathological Stage IB-IIIa Non Small Cell Lung Cancer

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention gemicitabine 1000mg/m2, day1 and day 8, every 3 week, 6 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention UFT 250mg/m2, daily for 1 year Find medicine records · Find other trials using this name

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2001-12-01

PhasePHASE3

Conditions

Lung Cancerverified · MONDO: lung cancer

Interventions

gemicitabine 1000mg/m2, day1 and day 8, every 3 week, 6DRUG

UFT 250mg/m2, daily for 1 yearDRUG

Sponsors & collaborators

West Japan Thoracic Oncology Grouplead sponsor

Mapped research locations

OsakaOsaka, Japan1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00139971 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.